The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors

• Verfasst von: Babyshkina, Nataliya [VerfasserIn]
• Verfasst von: Kzhyshkowska, Julia [VerfasserIn]
• Titel: The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors
• Titelzusatz: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen
• Verf.angabe: Nataliya Babyshkina, Sergey Vtorushin, Marina Zavyalova, Stanislav Patalyak, Tatyana Dronova, Nikolay Litviakov, Elena Slonimskaya, Julia Kzhyshkowska, Nadejda Cherdyntseva, Evgeny Choynzonov
• Jahr: 2017
• Jahr des Originals: 2016
• Umfang: 11 S.
• Fussnoten: Gesehen am 28.06.2018 ; Published online: 25 May 2016
• Titel Quelle: Enthalten in: Clinical and experimental medicine
• Ort Quelle: Milano : Springer, 2001
• Jahr Quelle: 2017
• Band/Heft Quelle: 17(2017), 3, Seite 383-393
• ISSN Quelle: 1591-9528
• DOI: doi:10.1007/s10238-016-0428-z
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1577015304

Abstract

Identification of additional biomarkers associated with ER genomic and nongenomic pathways could be very useful to distinguish patients who will benefit from tamoxifen treatment. The aim of this study was to analyze the prognostic significance of the distribution pattern of ERα expression, ESR1 gene single-nucleotide polymorphisms and expression levels of growth factor receptors in Russian hormone receptor-positive breast cancer patients treated with adjuvant tamoxifen. Formalin-fixed paraffin-embedded tumor tissue samples from 97 patients were examined for the distribution pattern of ERα expression, as well as for EGFR and TGF-βR1 expression by immunohistochemistry. Genotypes for ESR1 +30T>C (rs2077647) and ESR1 2014G>A (rs2228480) were analyzed using a TaqMan assay. Progression-free survival (PFS) was used as an endpoint for the survival analyses. We found that patients with the heterogeneous distribution of ERα expression had poor prognosis on tamoxifen treatment (P = 0.021). We identified a high EGFR expression in patients who developed distant metastasis or recurrence during tamoxifen treatment (a tamoxifen-resistant group-TR) in contrast to the distant metastasis-free patients (a tamoxifen-sensitive group-TS) (80.0 vs. 41.9 %, respectively, P = 0.009). Carriers of the ESR12014A mutant allele were more prevalent among the TR patients compared to the TS patients (26.3 vs. 8.0 %, respectively, P = 0.009). EGFR expression and the distribution pattern of ERα expression were associated with the response to tamoxifen by both univariate and multivariate logistic regression analyses. The presence of these markers either alone or in combination was correlated with the worse PFS for all patients. Analysis of the distribution pattern of ERα expression and the EGFR status in tumor tissue may be valuable for patient selection for tamoxifen adjuvant therapy.